Notas del episodio
A thin top-tier week for acromegaly (one Pituitary paper plus a handful of solid next-tier studies, including a 2026 pipeline review), while rare disease news was dominated by positive Phase 3 readouts from Disc Medicine and Roivant, a second FDA look at Biohaven's ataxia drug, and early Huntington's data from Alnylam.

